Compare +50 FDA Breakthrough Device Providers
If your team is deciding whether to outsource Breakthrough Device strategy, this page is built to help you compare providers by decision quality, not by marketing claims. The objective is simple: reduce avoidable timeline risk, align evidence planning to FDA expectations, and avoid overpaying for fragmented workstreams. Breakthrough Device designation can create important communication and review advantages, but only when your regulatory narrative, clinical rationale, and execution plan are tightly integrated.
What This Directory Covers
This directory is structured around provider capabilities most teams miss during selection: indication framing quality, alternatives analysis depth, evidence package realism, and governance after designation. The right partner is not just the one with prior submissions; it is the one that can defend assumptions under regulatory scrutiny while keeping your cross-functional team aligned.
Regulatory Strategy Evidence Planning Q-Sub Preparation Execution GovernanceHow To Evaluate Breakthrough Device Providers
Selection should start with outcome-oriented criteria. Ask each provider to show how they convert a clinical unmet-need claim into a testable, evidence-backed regulatory argument. Strong teams can explain exactly where uncertainty sits, what assumptions are reversible, and what data must be generated before key FDA interactions. Weak teams hide uncertainty in generic timelines and broad statements such as "we have done many submissions." For a high-stakes pathway, you need transparent constraints, not optimism.
Prioritize providers that can provide clear work products: indication mapping memo, alternatives landscape summary, decision log, evidence gap tracker, and meeting-readiness packs. If a provider cannot show sanitized examples of these assets, they likely depend on ad-hoc work that creates rework. You should also verify collaboration mechanics with your quality, clinical, and software teams, especially if your device has AI or cybersecurity exposure.
Signal 1: Problem Fit
Does the provider distinguish between severe disease burden and true unmet need in your proposed population?
Signal 2: Evidence Realism
Can they quantify likely data scope with scenario ranges rather than a single "best case" estimate?
Signal 3: Decision Quality
Do they maintain assumption logs, decision memos, and pivot triggers as part of routine governance?
Signal 4: Execution Integration
Can they coordinate regulatory, quality, and engineering documentation without duplicated narrative drift?
Provider Due-Diligence Checklist
Before you sign, require a short paid discovery sprint and define outputs upfront. You should receive a risk-ranked workplan, timeline assumptions, and a red-flag memo that identifies the top causes of designation failure for your profile. This approach is usually cheaper than entering a full contract based on generic promises.
- Request one anonymized example where the provider changed strategy after early FDA feedback.
- Ask how they separate "designation argument" from "future clearance argument" to avoid premature scope inflation.
- Verify who owns authoring vs review for core deliverables; unclear ownership drives delays.
- Require a transparent staffing model and escalation path when assumptions break.
- Confirm that budget estimates include documentation maintenance after FDA interactions.
Use These Planning Tools Before Final Provider Selection
We recommend running the calculators below first, then using outputs as objective checkpoints in provider interviews. This helps you compare proposals on equivalent assumptions instead of accepting each vendor's custom framing.
Get A Structured Shortlist
Build your shortlist around comparable assumptions, then evaluate each provider against the same risk model. This is how teams avoid expensive re-scoping late in the process.
Start With Structured PlanningReferences
[1] FDA, "Breakthrough Devices Program," guidance and program overview: FDA Program Page. [2] 21st Century Cures Act, section establishing Breakthrough Device framework: Public Law 114-255. [3] FDA Q-Submission resources for pre-submission interactions: Q-Submission Program.